Randomized Control Trial of Postnatal RhIGF-1/rhIGFBP-3 Replacement in Preterm Infants: Analysis of Its Effect on Brain Injury
Overview
Authors
Affiliations
Postnatal insulin-like growth factor-1 (IGF-1) replacement with recombinant human (rh)IGF-1 and IGF binding protein-3 (rhIGF-1/rhIGFBP-3) is being studied as a potential treatment to reduce comorbidities of prematurity. We have recently reported on a phase II, multicenter, randomized, controlled trial comparing postnatal rhIGF-1/rhIGFBP-3 replacement with standard of care (SOC) in extremely preterm infants (NCT01096784). Maximum severity of retinopathy of prematurity was the primary endpoint of the trial and presence of GMH-IVH/PHI one of the pre-specified secondary endpoints. Infants therefore received serial cranial ultrasound scans (CUS) between birth and term age. In this analysis we present a detailed analysis of the CUS data of this trial and evaluate the effect of postnatal rhIGF-1/rhIGFBP-3 replacement on the incidence of different kinds of brain injury in extremely preterm infants. This report is an exploratory analysis of a phase II trial in which infants <28 weeks gestational age were randomly allocated to rhIGF-1/rhIGFBP-3 or SOC. Serial cranial ultrasounds were performed between birth and term-equivalent age. Presence of germinal matrix hemorrhage and intraventricular hemorrhage (GMH-IVH), periventricular hemorrhagic infarction (PHI), post-hemorrhagic ventricular dilatation, and white matter injury (WMI) were scored by two independent masked readers. The analysis included 117 infants; 58 received rhIGF-1/rhIGFBP-3 and 59 received SOC. A trend toward less grade II-III GMH-IVH and PHI was observed in treated infants vs. SOC. A subanalysis of infants without evidence of GMH-IVH at study entry ( = 104) showed reduced progression to GMH-IVH in treated infants (25.0% [13/52] vs. 40.4% [21/52]; not significant). No effects of rhIGF-1/rhIGFBP-3 on WMI were observed. The potential protective effect of rhIGF-1/rhIGFBP-3 on the occurrence of GMH-IVH/PHI appeared most pronounced in infants with no evidence of GMH-IVH at treatment start.
Wassink G, Cho K, Mathai S, Lear C, Dean J, Gunn A Brain Commun. 2024; 6(6):fcae373.
PMID: 39507274 PMC: 11539755. DOI: 10.1093/braincomms/fcae373.
Neurofilament light chain associates with IVH and ROP in extremely preterm infants.
Sjobom U, Ohrfelt A, Pivodic A, Nilsson A, Blennow K, Zetterberg H Pediatr Res. 2024; .
PMID: 39317698 DOI: 10.1038/s41390-024-03587-5.
Ekstrom C, Ortenlof N, Kristiansson A, Holmqvist B, Jungner A, Vallius S Sci Rep. 2023; 13(1):19847.
PMID: 37963901 PMC: 10645867. DOI: 10.1038/s41598-023-46611-0.
Christiansen L, Ventura G, Holmqvist B, Aasmul-Olsen K, Lindholm S, Lycas M Front Neurosci. 2023; 17:1205819.
PMID: 37404461 PMC: 10315495. DOI: 10.3389/fnins.2023.1205819.
Insulin-Like Growth Factor-1 Supplementation Promotes Brain Maturation in Preterm Pigs.
Christiansen L, Holmqvist B, Pan X, Holgersen K, Lindholm S, Henriksen N eNeuro. 2023; 10(4).
PMID: 36973010 PMC: 10112548. DOI: 10.1523/ENEURO.0430-22.2023.